<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3425">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467840</url>
  </required_header>
  <id_info>
    <org_study_id>ABC-201</org_study_id>
    <nct_id>NCT04467840</nct_id>
  </id_info>
  <brief_title>Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia</brief_title>
  <official_title>Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in&#xD;
      Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the&#xD;
      potential of opaganib to improve and/or stabilize the clinical status of the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled&#xD;
      study with an adaptive design that will utilize a futility assessment. The study is planned&#xD;
      be performed in Italy, other EU countries, Russia, Brazil, Mexico and the US in up to&#xD;
      approximately 40 clinical sites.&#xD;
&#xD;
      After informed consent is obtained, patients will enter a screening phase for no more than 3&#xD;
      days, to determine eligibility. Approximately 270 eligible patients will be randomized and&#xD;
      receive either opaganib added to standard of care, or matching placebo added to standard of&#xD;
      care, in a randomization ratio of 1:1. Treatment assignments will remain blinded to the&#xD;
      patient, investigator and hospital staff, as well as the sponsor. As the approval and/or&#xD;
      guidance for treating COVID-19 are evolving, for this protocol, standard of care will be&#xD;
      defined by the recommended schemes of treatment according to the severity of the disease&#xD;
      based on local diagnostic and guideline documents such as the Temporary Methodic&#xD;
      Recommendations: Prophylactic, Diagnostics and Treatment of New Corona Virus Infection&#xD;
      (COVID-19) (Appendix 10); the EU Commission, the European Medicines Agency (EMA), the Heads&#xD;
      of Medicines Agency (HMA) and FDA, and as updated to the most current version of the&#xD;
      recommendations.&#xD;
&#xD;
      Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours,&#xD;
      or matching placebo, in addition to standard of care (pharmacological as defined above and/or&#xD;
      supportive) at any given institution. Study drug will be administered every day for 14 days&#xD;
      (Day 1 to Day 14). All participants will be followed up for 28 days after their last dose of&#xD;
      study drug, which may occur at Day 14 or after premature study drug discontinuation, based&#xD;
      upon patient or physician determination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation and mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the proportion of patients requiring intubation and mechanical ventilation by Day 14 between subjects taking opaganib and those on placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0</measure>
    <time_frame>14 days</time_frame>
    <description>Compare scores of subjects taking opaganib and those on placebo, lower scores indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intubation and mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the time to intubation and mechanical ventilation between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to low oxygen flow via nasal cannula</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the time to low oxygen flow via nasal cannula e.g. from high oxygen flow via nasal cannula or CPAP, if high oxygen flow is not an available option between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental oxygen requirement</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14 between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily oxygen requirement</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (L/min) over 14 days (Day 1 to Day 14) between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative swabs for SARS-CoV-2</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the time to two consecutive negative swabs for SARS-CoV-2 by PCR between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative swabs for SARS-CoV-2 at day 14</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the proportion of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the proportion of patients, with at least one measurement of fever at baseline (defined as temperature &gt;38.0 C [100.4 F]), who are afebrile (defined as temperature &lt;37.2C [99 F]) at Day 14 between subjects taking opaganib and those on placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days post baseline</time_frame>
    <description>To compare mortality 30 days post-baseline between subjects taking opaganib and those taking placebo</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 14 days and at the end of the 4 weeks follow-up after the end of treatment</time_frame>
    <description>To compare the number of adverse events in patients with severe COVID-19 pneumonia between subjects taking opaganib and subjects taking placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers - D-dimer</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the change in the systemic marker of inflammation, D-dimer, over the treatment period between subjects taking opaganib and those on placebo.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers - cardiac troponin</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the change in the systemic marker of inflammation, cardiac troponin, over the treatment period between subjects taking opaganib and those on placebo.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers - C-reactive protein</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the change in the systemic marker of inflammation, C-reactive protein [CRP], over the treatment period between subjects taking opaganib and those on placebo.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers - lactate dehydrogenase</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the change in the systemic marker of inflammation lactate dehydrogenase [LDH] over the treatment period between subjects taking opaganib and those on placebo.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers - ferritin</measure>
    <time_frame>14 days</time_frame>
    <description>To compare the change in the systemic marker of inflammation ferritin over the treatment period between subjects taking opaganib and those on placebo.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>COVID-19</condition>
  <condition>Lung Infection</condition>
  <arm_group>
    <arm_group_label>Opaganib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard of care, opaganib will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. When required this may be made into a suspension form and may be administered by nasogastric tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In addition to standard of care, a matching placebo will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. Where required this may be made into a suspension form and may be administered by nasogastric tube.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opaganib</intervention_name>
    <description>Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).</description>
    <arm_group_label>Opaganib</arm_group_label>
    <other_name>Yeliva</other_name>
    <other_name>ABC294640</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male or female ≥18 to ≤80 years of age&#xD;
&#xD;
          2. Proven COVID-19 infection per RT-PCR assay of a pharyngeal sample (nasopharyngeal or&#xD;
             oropharyngeal) AND pneumonia defined as radiographic opacities on chest X-ray or CT&#xD;
             scan. that diagnosed COVID-19 pneumonia. Pharyngeal samples collected either at&#xD;
             screening or within 7-days prior to screening for the same ongoing COVID-19 pneumonia&#xD;
             illness are acceptable&#xD;
&#xD;
          3. The patient requires, at baseline, high flow supplemental oxygen or CPAP, if high&#xD;
             oxygen flow is not an available option.&#xD;
&#xD;
          4. Patient agrees to use appropriate methods of contraception during the study and 3&#xD;
             months after the last dose of study drug&#xD;
&#xD;
          5. The patient or legal representative has signed a written informed consent approved by&#xD;
             the IRB/Ethics Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any co-morbidity that may add risk to the treatment in the judgement of the&#xD;
             investigator.&#xD;
&#xD;
          2. Requiring intubation and mechanical ventilation at baseline&#xD;
&#xD;
          3. Patient has a 'Do Not Intubate' and/or 'Do Not Resuscitate' order in place&#xD;
&#xD;
          4. Oxygen saturation &gt;95% on room air&#xD;
&#xD;
          5. Any preexisting respiratory condition that requires intermittent or continuous&#xD;
             ambulatory oxygen prior to hospitalization&#xD;
&#xD;
          6. Patient is, in the investigator's clinical judgement, unlikely to survive &gt;72 hours&#xD;
&#xD;
          7. Pregnant (positive serum or urine test within 3 days prior to randomization) or&#xD;
             nursing women .&#xD;
&#xD;
          8. Unwillingness or inability to comply with procedures required in this protocol.&#xD;
&#xD;
          9. Corrected QT (QTc) interval on electrocardiogram (ECG) &gt;470 ms for females or &gt;450 ms&#xD;
             for males, calculated using Friedericia's formula (QTcF)&#xD;
&#xD;
         10. AST (SGOT) or ALT (SGPT) &gt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
         11. Total bilirubin &gt;1.5x ULN (except where bilirubin increase is due to Gilbert's&#xD;
             Syndrome)&#xD;
&#xD;
         12. Serum creatinine &gt;2.0 X ULN&#xD;
&#xD;
         13. Absolute neutrophil count &lt;1000 cells/mm3&#xD;
&#xD;
         14. Platelet count &lt;75,000/mm3&#xD;
&#xD;
         15. Hemoglobin &lt;8.0 g/dL&#xD;
&#xD;
         16. Medications that are sensitive substrates, or substrates with a narrow therapeutic&#xD;
             range, for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 CYP2D6 , CYP3A4, P-gP, BCRP and&#xD;
             OATP1B1. These should be decided in discussion with the Medical Monitor on a&#xD;
             case-by-case basis.&#xD;
&#xD;
         17. Moderate or strong inhibitors of CYP1A2, CYP3A4, CYP2D6 or P-gP or moderate to strong&#xD;
             inducers of CYP3A4 and CYP1A2. These should be decided in discussion with the Medical&#xD;
             Monitor on a case-by-case basis.&#xD;
&#xD;
         18. Currently taking warfarin, apixaban, argatroban or rivaroxaban due to drug-drug&#xD;
             interaction based on CYP450 metabolism&#xD;
&#xD;
         19. Current drug or alcohol abuse&#xD;
&#xD;
         20. Currently participating in a clinical study assessing pharmacological treatments,&#xD;
             including anti-viral studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark L Levitt, MD</last_name>
    <role>Study Director</role>
    <affiliation>RedHill Biopharma Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Levitt, MD</last_name>
    <phone>+972-3-541-3131</phone>
    <email>info@redhillbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vered Katz Ben-Yair, MSc</last_name>
    <phone>+972-3-541-3131</phone>
    <email>vered@redhillbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ABC-201 Site 408</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 411</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 405</name>
      <address>
        <city>Joinville</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 404</name>
      <address>
        <city>Paraná</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 410</name>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 409</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 401</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 402</name>
      <address>
        <city>São Bernardo Do Campo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 403</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 407</name>
      <address>
        <city>Tubarão</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 604</name>
      <address>
        <city>Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 603</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 605</name>
      <address>
        <city>Cundinamarca</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 602</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 601</name>
      <address>
        <city>Santiago de Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 702</name>
      <address>
        <city>Ashdod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 704</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 701</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 705</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 706</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 703</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 203</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 201</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 202</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 204</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 501</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 503</name>
      <address>
        <city>Sinaloa</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RedHill Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 110</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 122</name>
      <address>
        <city>Kirovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 101</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 132</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 120</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 103</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 114</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 129</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 108</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 102</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 109</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 111</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 104</name>
      <address>
        <city>Tver</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 118</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ABC-201 Site 112</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

